Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 10;39(5):BSR20190475.
doi: 10.1042/BSR20190475. Print 2019 May 31.

LncRNA TP73-AS1 down-regulates miR-139-3p to promote retinoblastoma cell proliferation

Zhaoxia Xia  1 , Xiaoxi Yang  2 , Shuduan Wu  2 , Zhizhen Feng  2 , Lei Qu  2 , Xianghua Chen  2 , Linyu Liu  2 , Yanling Ma  2
Affiliations

LncRNA TP73-AS1 down-regulates miR-139-3p to promote retinoblastoma cell proliferation

Zhaoxia Xia et al. Biosci Rep. .

Abstract

Our study aimed to investigate the role of long non-coding RNAs (lncRNA) TP73-AS1 in retinoblastoma (Rb). In the present study, we found that TP73-AS1 was up-regulated, while miR-139-3p was down-regulated in Rb. TP73-AS1 and miR-139-3p were inversely correlated in Rb tissues. In cells of Rb cell lines, overexpression of miR-139-3p failed to affect TP73-AS1, while TP73-AS1 overexpression caused the down-regulated miR-139-3p TP73-AS1 overexpression caused promoted proliferation of Rb cells but showed no significant effects on cell migration and invasion. miR-139-3p overexpression played an opposite role and attenuated the effects of TP73-AS1 overexpression. Therefore, lncRNA TP73-AS1 may down-regulate miR-139-3p to promote Rb cell proliferation.

Keywords: lncRNA TP73-AS1; miR-139-3p; proliferation; retinoblastoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests associated with the manuscript.

Figures

Figure 1
Figure 1. TP73-AS1 and miR-139-3p were dysregulated in Rb tissues
Analysis of TP73-AS1 and miR-139-3p expression data showed that TP73-AS1 was significantly up-regulated (A), while miR-139-3p was significantly down-regulated (B) in Rb tissues than in non-cancer tissues of Rb patients (*P<0.05).
Figure 2
Figure 2. TP73-AS1 and miR-139-3p were affected by the development of Rb
Analysis of TP73-AS1 and miR-139-3p analysis by one-way ANOVA and Tukey test showed that expression levels of TP73-AS1 increased (A), while expression levels of miR-139-3p decreased (B) with the development of Rb. Group A, tumor size below 3 mm, not lose to foveola or optic disc, only in the retina; Group B, tumor larger than 3 mm, close to foveola or optic disc, only in the retina; Group C, small amounts of spread into the jelly-like material or under the retina; Group D, subretinal seeding or widespread vitreous; Group E, large tumor extends near the front of the eye, glaucoma or bleeding, (*P<0.05).
Figure 3
Figure 3. TP73-AS1 and miR-139-3p were inversely correlated
Linear regression revealed a significant and reverse correlation between TP73-AS1 and miR-139-3p was found in Rb tissues (A), but not in non-cancer tissues (B).
Figure 4
Figure 4. TP73-AS1 down-regulated miR-139-3p to promote the proliferation of Rb cells
Comparing to C (Control) and NC (Negative control), expression levels of TP73-AS1 and miR-139-3p were significantly up-regulated at 24 h after transfection (A). Comparing to the two controls, overexpression of miR-139-3p failed to affect TP73-AS1 (B), while TP73-AS1 overexpression caused down-regulated miR-139-3p (C). Moreover, TP73-AS1 overexpression caused promoted proliferation of both WERI-Rb-1 and Y79 cells (D). In addition, miR-139-3p overexpression played an opposite role and attenuated the effects of TP73-AS1 overexpression (*P<0.05).
See this image and copyright information in PMC

References

    1. Shields C.L. and Shields J.A. (2010) Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr. Opin. Ophthalmol. 21, 203–212 10.1097/ICU.0b013e328338676a - DOI - PubMed
    1. Shields C.L., Lally S.E., Leahey A.M., Jabbour P.M., Caywood E.H., Schwendeman R.. et al. (2014) Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr. Opin. Ophthalmol. 25, 374–385 10.1097/ICU.0000000000000091 - DOI - PubMed
    1. Chévez-Barrios P., Hurwitz M.Y., Louie K.. et al. (2000) Metastatic and nonmetastatic models of retinoblastoma. Am. J. Pathol. 157, 1405–1412 10.1016/S0002-9440(10)64653-6 - DOI - PMC - PubMed
    1. Shields C.L., Mashayekhi A., Au A.K.. et al. (2006) The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 113, 2276–2280 10.1016/j.ophtha.2006.06.018 - DOI - PubMed
    1. Zage P.E., Reitman A.J., Seshadri R.. et al. (2008) Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr. Blood Cancer 50, 567–572 10.1002/pbc.21301 - DOI - PubMed

Publication types

MeSH terms